Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First results of migoprotafib, a potent and highly selective Src homology-2 domain-containing phosphatase 2 (SHP2) inhibitor in patients with advanced solid tumors.
Johnson ML, Wolf BB, Wang JS, Philipovskiy A, Shapiro GI, Bockorny B, Guo W, Shen J, Jen KY, LeRose M, Hunter TL, Padval M, Schmidt-Kittler O, Bhatia N, Dubey S, Suchomel J, Bendell JC, Jauhari S, Eng-Wong J, Lin JJ. Johnson ML, et al. Among authors: hunter tl. Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0466. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39632729
Gradient-Elution Nanoflow Liquid Chromatography Without a Binary Pump: Smoothed Step Gradients Enable Reproducible, Sensitive, and Low-Cost Separations for Single-Cell Proteomics.
Webber KGI, Huang S, Lin HL, Hunter TL, Tsang J, Jayatunge D, Andersen JL, Kelly RT. Webber KGI, et al. Among authors: hunter tl. Mol Cell Proteomics. 2024 Dec;23(12):100880. doi: 10.1016/j.mcpro.2024.100880. Epub 2024 Nov 12. Mol Cell Proteomics. 2024. PMID: 39536954 Free PMC article.
Prehabilitation in radiation therapy: a scoping review.
Flores LE, Westmark D, Katz NB, Hunter TL, Silver EM, Bryan KM, Jagsi R, McClelland S 3rd, Silver JK. Flores LE, et al. Among authors: hunter tl. Support Care Cancer. 2024 Jan 5;32(1):83. doi: 10.1007/s00520-023-08262-9. Support Care Cancer. 2024. PMID: 38177946 Review.
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, Bulku A, DiPietro L, Fridrich C, Frost A, Giordanetto F, Hamilton EP, Harris K, Holliday M, Hunter TL, Iskandar A, Ji Y, Larivée A, LaRochelle JR, Lescarbeau A, Llambi F, Lormil B, Mader MM, Mar BG, Martin I, McLean TH, Michelsen K, Pechersky Y, Puente-Poushnejad E, Raynor K, Rogala D, Samadani R, Schram AM, Shortsleeves K, Swaminathan S, Tajmir S, Tan G, Tang Y, Valverde R, Wehrenberg B, Wilbur J, Williams BR, Zeng H, Zhang H, Walters WP, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Fraser JS, Fortin PD, Kipp DR. Varkaris A, et al. Among authors: hunter tl. Cancer Discov. 2024 Feb 8;14(2):240-257. doi: 10.1158/2159-8290.CD-23-0944. Cancer Discov. 2024. PMID: 37916956 Free PMC article.
Cancer Prehabilitation in Practice: the Current Evidence.
Coderre D, Brahmbhatt P, Hunter TL, Baima J. Coderre D, et al. Among authors: hunter tl. Curr Oncol Rep. 2022 Nov;24(11):1569-1577. doi: 10.1007/s11912-022-01304-1. Epub 2022 Jul 5. Curr Oncol Rep. 2022. PMID: 35788874 Review.
Author Diversity on Clinical Practice Guideline Committees.
Verduzco-Gutierrez M, Katz NB, Fleming TK, Silver EM, Hunter TL, El Sayed N, Escalon MX, Lorello GR, Silver JK. Verduzco-Gutierrez M, et al. Among authors: hunter tl. Am J Phys Med Rehabil. 2022 May 1;101(5):493-503. doi: 10.1097/PHM.0000000000001932. Epub 2021 Nov 15. Am J Phys Med Rehabil. 2022. PMID: 34775456
21 results